Compounds > isotetrandrine
Page last updated: 2024-12-05

isotetrandrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID457825
CHEMBL ID449690
SCHEMBL ID718928
MeSH IDM0054139

Synonyms (59)

Synonym
NCIMECH_000062
ccris 6540
isosinomenin a
o,o'-dimethylobamegine
nsc 97338
o-methylberbamine
o,o'-dimethylstepholine
berbaman, 6,6',7,12-tetramethoxy-2,2'-dimethyl-
NCGC00013832-02
cas-518-34-3
tnp00326
NCGC00017376-01
isosinomenine a
6,6',7,12-tetramethoxy-2,2'-dimethylberbaman
(r,s)-tetrandrine
tetramethoxy(dimethyl)[?]
NCGC00013832
isotetrandrine ,
1-isotetrandrine
477-57-6
(+)-isotetrandrine
NCI77037
NCISTRUC1_000265
NCISTRUC2_000039
NCGC00096942-01
smr001397085
MLS002472978
CHEMBL449690
84t861cp2n ,
unii-84t861cp2n
bdbm85444
pheanthine (r,r)
isotetrandrine (r,s)
HMS2226F20
CCG-36288
NCGC00013832-03
SCHEMBL718928
16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinoline, 3,4,4a,5,16a,17,18,19-octahydro-12,21,22,26-tetramethoxy-4,17-dimethyl-, (4as,16ar)-
isotetrandrine [who-dd]
16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinoline, 3,4,4a,5,16a,17,18,19-octahydro-12,21,22,26-tetramethoxy-4,17-dimethyl-, (4as-(4ar*,16as*))-
5956-77-4
isotetrandrine, (+)-
AKOS030497625
23495-90-1
SW219720-1
isotetrandine
(11s,31r)-16,36,37,54-tetramethoxy-12,32-dimethyl-11,12,13,14,31,32,33,34-octahydro-2,6-dioxa-1(7,1),3(8,1)-diisoquinolina-5(1,3),7(1,4)-dibenzenacyclooctaphane
(+/-)-isotetrandrine
C7WJK43784 ,
isotetrandrine, (+/-)-
unii-c7wjk43784
1-isotetrandrine, (+/-)-
berbaman, 6,6',7,12-tetramethoxy-2,2'-dimethyl-, (+/-)-
CS-0032236
berbamine methyl ether
MS-30800
HY-N6045
DTXSID501316772
(1s,14r)-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency19.95260.044717.8581100.0000AID485341
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency23.10930.000811.382244.6684AID686978; AID686979
thioredoxin glutathione reductaseSchistosoma mansoniPotency35.48130.100022.9075100.0000AID485364
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
importin subunit beta-1 isoform 1Homo sapiens (human)Potency50.11875.804836.130665.1308AID540263
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency10.00000.65619.452025.1189AID927
snurportin-1Homo sapiens (human)Potency50.11875.804836.130665.1308AID540263
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency56.23410.425612.059128.1838AID504891
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency11.00950.004611.374133.4983AID624296; AID624297
lethal factor (plasmid)Bacillus anthracis str. A2012Potency22.10610.020010.786931.6228AID912
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency10.00000.316212.765731.6228AID881
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency10.00000.00638.235039.8107AID881
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency10.00001.584913.004325.1189AID927
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID337519Cytotoxicity against human BCA1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337550Selectivity index, ratio of ED50 for human ZR-75-1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337520Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337524Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1663396Inhibition of P-glycoprotein-mediated Rhodamine-123 efflux in human MOLT4/DNR cells assessed as inhibition of P-glycoprotein efflux function at 1 uM incubated for 1 hr by flow cytometry2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
AID337545Selectivity index, ratio of ED50 for mice (Mus musculus) P388 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1663397Inhibition of P-glycoprotein-mediated Rhodamine-123 efflux in human MOLT4/DNR cells assessed as inhibition of P-glycoprotein efflux function at 10 uM incubated for 1 hr by flow cytometry2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
AID337518Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337533Selectivity index, ratio of ED50 for human HT1080 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID377948Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum W21999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID377945Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID377944Cytotoxicity against human KB cells after 72 hrs by SRB assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID337535Selectivity index, ratio of ED50 for human LUC1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337541Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337525Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337548Selectivity index, ratio of ED50 for human LNCaP cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337551Selectivity index, ratio of ED50 for human ZR-75-1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337543Selectivity index, ratio of ED50 for human KB-V1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337530Selectivity index, ratio of ED50 for human BCA1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337537Selectivity index, ratio of ED50 for human MEL2 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337527Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337549Selectivity index, ratio of ED50 for human LNCaP cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337536Selectivity index, ratio of ED50 for human MEL2 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337523Cytotoxicity against human Col1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID333842Cytotoxicity against human KB cells
AID337544Selectivity index, ratio of ED50 for mice (Mus musculus) P388 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337547Selectivity index, ratio of ED50 for human A431 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337517Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337526Cytotoxicity against mouse P388 cells after 2 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337531Selectivity index, ratio of ED50 for human BCA1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1663395Inhibition of P-glycoprotein-mediated Rhodamine-123 efflux in human MOLT4/DNR cells assessed as inhibition of P-glycoprotein efflux function at 0.3 uM incubated for 1 hr by flow cytometry2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
AID337529Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID377947Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID337546Selectivity index, ratio of ED50 for human A431 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337539Selectivity index, ratio of ED50 for human COL1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID377946Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum D61999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID337522Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337540Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337532Selectivity index, ratio of ED50 for human HT1080 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337521Cytotoxicity against human LUC1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337528Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337542Selectivity index, ratio of ED50 for human KB-V1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337538Selectivity index, ratio of ED50 for human COL1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337534Selectivity index, ratio of ED50 for human LUC1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1799661Inhibition Assay from Article 10.3109/14756369809035823: \\Trypanocidal bisbenzylisoquinoline alkaloids are inhibitors of trypanothione reductase.\\1998Journal of enzyme inhibition, Feb, Volume: 13, Issue:1
Trypanocidal bisbenzylisoquinoline alkaloids are inhibitors of trypanothione reductase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (33.33)18.2507
2000's1 (11.11)29.6817
2010's3 (33.33)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.3920aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
mefloquine hydrochloride
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.		2.3920organofluorine compound;
piperidines;
quinolines;
secondary alcohol
cepharanthine
cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.		2.7130bisbenzylisoquinoline alkaloid;
isoquinolines
tetrandrine
tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity		2.4620bisbenzylisoquinoline alkaloid;
isoquinolines
dauricine
dauricine: RN given refers to parent cpd. dauricine : A bisbenzylisoquinoline alkaloid resulting from the formal oxidative dimerisation of 4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenol by attachment of the phenolic oxygen of one molecule to the benzene ring of the second (ortho to the phenolic hydroxy group of the latter).		2.2510aromatic ether;
bisbenzylisoquinoline alkaloid;
isoquinolines;
phenols;
tertiary amino compound		plant metabolite
fangchinoline
[no description available]		2.4620aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle		anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite
fangchinoline
fangchinoline: RN given refers to parent cpd; limacine is the (1'beta)-isomer; 7-O-demethyltetrandrine is the (1S,1'S)-isomer. fangchinoline : A bisbenzylisoquinoline alkaloid that is (1beta)- berbaman which has been substituted by methyl groups at the 2 and 2' positions, by methoxy groups at the 6, 6', and 12 positions, and by a hydroxy group at position 7. Isolated from Stephania tetrandra, it has been found to possess neuroprotective and anti-tumour activity.		2.6830
cycleanine
cycleanine: a bisbenzyl-bisisoquinoline alkaloid isolated from Chinese herb Stephania epigeae Lu; used for controlling blood pressure during anesthesia; RN refers to the R,R-isomer (cycleanine); isocycleanine is the R,S-isomer;		1.9910bisbenzylisoquinoline alkaloid;
isoquinolines
trilobine
trilobine: RN given refers to parent cpd		210isoquinolines
chondocurine (1beta)-(+-)-isomer
curine: structure in first source		1.9910aromatic ether
berbamine
[no description available]		2.4620bisbenzylisoquinoline alkaloid;
isoquinolines
aromoline
aromoline: from roots of Stephania cepharantha; structure given in first source		210
obamegine
obamegine: RN given refers to cpd without isomeric designation		210bisbenzylisoquinoline alkaloid;
isoquinolines
quinine
[no description available]		2.3920cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510